Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 20/20 | 1.00 |
| ▸ | HTR2C | P28335 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209963 | 0.90 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5213095 | 0.87 | HTR2A (0.77) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5216193 | 0.86 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5210811 | 0.86 | HTR2A (0.87) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5213008 | 0.86 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5213211 | 0.85 | HTR2A (0.85) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5216429 | 0.85 | KCNH2 (0.74) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5208754 | 0.83 | HTR2A (0.96) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5217103 | 0.83 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 | |
| SCHEMBL5210934 | 0.83 | HTR2A (1.00) | HTR2AHTR2CKCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211735-A1 | 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | MERCK SHARP & DOHME LTD. (GB) | 2006-09-21 | — | — | US | claimed |
| EP-1641756-B1 | 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR | MERCK SHARP & DOHME (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20060211735-A1 | 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | MERCK SHARP & DOHME LTD. (GB) | 2006-09-21 | — | — | US | disclosed |
| EP-1641756-A1 | 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR | MERCK SHARP & DOHME LTD. (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004101518-A1 | 4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT2A RECEPTOR | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211735-A1 | 4-Arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor | HTR2A, HTR2C, HTR5A | HTR2A 1/4885HTR2C 2/4885KCNH2 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.